SCHEMBL29456476

SCHEMBL29456476

Cc1cc(N2CCCCC[C@@H]2c2ccc(S(C)(=O)=O)cc2C)nc(N)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 2/20 0.43
CRHR2 Q13324 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSP90AA1 P07900 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MAPT P10636 2/20 0.36
ROCK1 Q13464 1/20 0.36
PTGS2 P35354 1/20 0.36
KDM4E B2RXH2 1/20 0.36
HRH4 Q9H3N8 2/20 0.35
HRH3 Q9Y5N1 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
GFER P55789 1/20 0.34
NR1H2 P55055 1/20 0.34
NR1H3 Q13133 1/20 0.34
CFB P00751 1/20 0.33
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21516196 1.00 CRHBP (0.43) CRHBPCRHR2SMN1; SMN2HSP90AA1L3MBTL1
SCHEMBL23036742 1.00 CRHBP (0.43) CRHBPCRHR2SMN1; SMN2HSP90AA1L3MBTL1
SCHEMBL21491283 0.88 CRHBP (0.40) CRHBPCRHR2SMN1; SMN2HSP90AA1L3MBTL1
SCHEMBL21516633 0.88 CRHBP (0.40) CRHBPCRHR2SMN1; SMN2HSP90AA1L3MBTL1
SCHEMBL29456485 0.88 CRHBP (0.40) CRHBPCRHR2SMN1; SMN2HSP90AA1L3MBTL1
SCHEMBL21516203 0.88 CRHBP (0.40) CRHBPCRHR2SMN1; SMN2HSP90AA1L3MBTL1
SCHEMBL25491575 0.85 SMN1; SMN2 (0.49) CRHBPCRHR2SMN1; SMN2HSP90AA1L3MBTL1
SCHEMBL21516847 0.82 CRHBP (0.44) CRHBPCRHR2SMN1; SMN2HSP90AA1L3MBTL1
SCHEMBL23036719 0.82 CRHBP (0.50) CRHBPCRHR2SMN1; SMN2HSP90AA1L3MBTL1
SCHEMBL21516967 0.82 CRHBP (0.50) CRHBPCRHR2SMN1; SMN2HSP90AA1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188070-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2025-06-12 US disclosed
CN-112236428-B Antiproliferative compounds and uses thereof 默克专利股份有限公司 2025-04-01 CN disclosed
US-12195453-B2 Antiproliferation compounds and uses thereof MERCK PATENT GMBH (DE) 2025-01-14 US disclosed
EP-4043460-B1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2024-06-05 EP disclosed
US-20230150993-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2023-05-18 US disclosed
US-11440907-B1 Antiproliferation compounds and uses thereof MERCK PATENT GMBH (DE) 2022-09-13 US disclosed
EP-4043460-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF Merck Patent GmbH (DE) 2022-08-17 EP disclosed
EP-3784666-B1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2022-03-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12195453-B2 Antiproliferation compounds and uses thereof MKI67, MCL1, CCNI CRHBP 4181/4885CRHR2 4068/4885SMN1; SMN2 2714/4885
US-11440907-B1 Antiproliferation compounds and uses thereof MKI67, MCL1, CCNI CRHBP 4181/4885CRHR2 4068/4885SMN1; SMN2 2714/4885
US-20230150993-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MKI67, MCL1, CCNI CRHBP 4181/4885CRHR2 4068/4885SMN1; SMN2 2714/4885
US-20250188070-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MKI67, MCL1, CCNI CRHBP 4181/4885CRHR2 4068/4885SMN1; SMN2 2714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.